Related Experiment Videos
Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C
R Vezza1, R Roberti, G G Nenci
1Institute of Internal and Vascular Medicine, University of Perugia, Italy.
Blood
|November 1, 1993
Summary
Prostaglandin E2 (PGE2) enhances platelet activation at low concentrations by priming protein kinase C (PKC), promoting aggregation and secretion. This effect is relevant in pathophysiological conditions involving activated platelets.
Area of Science:
- Biochemistry
- Hematology
- Cell Signaling
Background:
- Prostaglandin E2 (PGE2) has a dual role in platelet aggregation, being inhibitory at high concentrations and potentiating at low concentrations.
- The precise biochemical mechanisms underlying PGE2's proaggregatory effects on human platelets remain largely unknown.
- Activated platelets and endothelial cells are sources of PGE2, highlighting its potential role in hemostasis and thrombosis.
Purpose of the Study:
- To investigate the biochemical mechanisms of Prostaglandin E2 (PGE2)-mediated proaggregatory effects on human platelets.
- To analyze the second messenger pathways involved in PGE2's potentiation of platelet activation.
- To determine the role of protein kinase C (PKC) in PGE2-induced platelet responses.
Main Methods:
- Evaluation of PGE2's activity on human platelet aggregation and intracellular calcium transients at various concentrations.
- Assessment of PGE2's effect on platelet secretion (beta-thromboglobulin, ATP) and fibrinogen binding.
- Measurement of 47-kD protein phosphorylation and inhibition of PGE2-mediated aggregation using specific protein kinase C (PKC) inhibitors.
Main Results:
- Low concentrations of PGE2 (5-500 nmol/L) significantly enhanced platelet aggregation and secretion induced by agonists like U46619, thrombin, ADP, and PMA, without increasing calcium.
- High PGE2 concentration (50 mumol/L) inhibited both platelet aggregation and calcium mobilization.
- PGE2 potentiated agonist-induced fibrinogen binding and 47-kD protein phosphorylation, an effect abolished by PKC inhibitors, suggesting PKC activation.
Conclusions:
- PGE2 at pathophysiologically relevant concentrations potentiates agonist-induced platelet activation.
- PGE2 facilitates platelet activation by priming protein kinase C (PKC) for enhanced responsiveness to other agonists.
- These findings elucidate a key mechanism for PGE2's role in platelet function and potential thrombotic events.